[ 메디채널 김갑성 기자 ] —— Globally Pioneering POGMENT Triple-Helix Biomimetic Collagen Debuts at Chinese Biomaterials Congress 2025

CHENGDU, China, Oct. 14, 2025 -- The 2025 Chinese Biomaterials Congress was recently held in Shaoxing, Zhejiang, gathering leading experts including academicians from the Chinese Academy of Engineering and the Chinese Academy of Sciences, together with international figures such as U.S. National Academy of Engineering member Leonard Pinchuk, UK Royal Society Fellow Molly Stevens, and Professor Kunio Ishikawa, President of the Japanese Society for Biomaterials.

LivingPhoenix Regenerative Technologies Development (Chengdu) Co., Ltd., recognized as the world's first company dedicated to the research and industrialization of triple-helix biomimetic collagen, was invited to present its achievements. Its debut presentation drew wide attention from academia and industry alike.

At the session on Biomimetic and Life-Like Materials, Founder Mr. Qin Xingjiong introduced the study "Safety and Efficacy Evaluation of Chemically Synthesized Triple-Helix Biomimetic Collagen," conducted jointly with Beijing Hospital, Peking University Third Hospital, Shanghai Ninth People's Hospital, and The University of Tokyo. The peer-reviewed results, published in Frontiers in Bioengineering and Biotechnology (April 2025, SCI Q1), confirmed the material's safety, thermal stability, and biocompatibility, demonstrating strong potential for regenerative medicine.

The technology originated from research launched in 2001 by Professor Masao Tanihara of Kyoto University and was further developed through collaboration with Nara Institute of Science and Technology and others. In 2023, Dr. Takafumi Takebayashi joined LivingPhoenix^® with core intellectual property, forming a new R&D team led by Dr. Zhou Boyu of The University of Tokyo. The team advanced the technology from version 1.0 to 2.0, earning multiple invention patents. In addition, the international PCT is also under application.

According to Dr. Zheng Yongli of Chengdu Gaoyuan Intellectual Property Agency, comparative analysis of 240 related patents verified the technology as "world-first and internationally leading." Version 2.0 improves stability through "PISA in water" processing and achieved the world's first Cryo-TEM imaging of collagen fibrils.

The product has completed NMPA medical device master file and cosmetic ingredient filings. Its injectable biomimetic collagen lyophilized fiber is classified as a Class III medical device, with future applications planned for cosmetics, medical dressings, implants, and tissue engineering.

For collaboration opportunities in cosmetics, medical aesthetics, or high-end biomaterials, contact:

Email：POGMENT@mylivingphoenix.com
Official website：www.mylivingphoenix.com